Rossari Biotech Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/siv4ib9l61bc2erltrp2hwk4.pdf

Key Takeaways


Demand & Pricing Environment

Chari: "Every day, there is uncertainty on what is going to be happening next. This uncertainty is killing."

Capacity Expansion & Capex


New Products & R&D Pipeline


Segment & Business Performance

SegmentTrendCommentary
Core B2B▬ Steady at lower marginEBITDA margin fell from 15.8% to 14.8% on product mix and ~₹3.5 crore of additional maintenance at Tristar and Dahej; expected to range 14-16% going forward.
Textile Chemicals▲ QoQ growth, tariff overhang10% QoQ growth but US tariffs creating headwinds for home textiles and garments; margin pressure expected as suppliers share risk.
International Business▲ Strong36% YoY in Q2, 27% in H1, driven by deeper penetration with key customers and new geographies.
Institutional & B2C▼ Soft, improvingOnly 1% YoY growth but losses reduced through efficiency efforts; remains a drag on consolidated margins.
Buzil-Rossari▬ Muted growth, margin focusRevenue grew only 1.4% vs 25%+ historically because the company is deliberately restricting low-margin products to improve profitability.

Margins & Profitability

Sablok: "This year I think, at least now it's a little difficult for us to really predict how the year is going to end up, but if we can maintain these kinds of margins for this year I think we would be quite happy."

Working Capital & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
Dahej capacity peak utilizationNew plant to reach full utilizationBy FY28
Second-phase capacity commissioningRemaining 30,000 MTPA expansion and other additionsOver coming quarters
Working capital normalizationReturn to positive operating cash flowBy year-end (2 quarters)
Thailand blending unitOn streamEnd of Q3 FY26
Vitamin/mineral premix plantInto productionEnd of this month
Core B2B EBITDA margin14% – 16% rangeH2 FY26
Gross marginRemain the same as current levelsComing quarters
Expense levelsRemain at H1 levelsRest of FY26
Debt levelStabilize at current numberNo timeline; stated expectation
Margin expansionLargely rests in FY27 when continuous facility and EO availability improveFY27

Key Metrics

MetricQ2 FY26
Revenue₹586.1 crore, +18% YoY
EBITDA₹71.9 crore, margin of 12.3% vs 13.2% in Q2 last year
Core EBITDA margin (excl. institutional and B2C)~15%, steady; was 15.8% last year, now 14.8%
HPPC division growth+16% YoY
TSC division growth+21% YoY
AHN division growth+29% YoY
Exports growth+36% YoY in Q2, +27% in H1
Export revenue share~28% of overall revenues
Institutional and B2C business growth~1% YoY, +7% QoQ
Textile chemicals growth+10% QoQ
Net working capital days102 days, vs 95 days in March
Total planned capital outlay₹192 crore
H1 FY26 capex outflow~₹142 crore, with another ₹20–25 crore expected
One-time expenses in the quarter~₹2.5 crore
Additional maintenance expense (Tristar and Dahej)~₹3.5 crore
Ethoxylation capacity at Unitop Dahej~30,000 tons, running at full utilization 24/7
New capacity commissioned at Dahej20,000 metric tons per annum
New ethoxylation capacity at Unitop15,000 metric tons per annum, first phase of planned 30,000
Expected asset turns at full utilization3–4x
Revenue potential with additional capacity~₹3,500 crore (per an analyst's math, management called it a fair assumption)
Estimated capacity at end of FY26~385,000 tons
Board-approved investment in Saudi Arabia subsidiaryUp to USD 8 million
Direct export exposure to US12–14% of exports
HPPC export-domestic split~30% exported, ~70% domestic